Corporate Banner
Satellite Banner
Technology Networks Header
Monday, February 02, 2015
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Novel Organoid Matrix Enables Long-Term Culture of Human Hepatocytes
Organoid growth matrix to enable long-term culture of genome-stable bipotent stem cells from adult human liver.
New Metabolic Biomarkers Predict Future Cardiovascular Diseases
Scientists of the Helmholtz Zentrum München contributed to the analysis of the biomarkers.
Study Links Deficiency of Cellular Housekeeping Gene with Aggressive Forms of Breast Cancer
Research team studies genes involved in the autophagy process and their roles in cancer, aging, infections, and neurodegenerative diseases.
New Method For Identifying Most Aggressive Childhood Cancers
A research group at Lund University in Sweden has found a new way to identify the most malignant tumours in children. The method involves studying genetic ‘micro-variation’, rather than the presence of individual mutations.
Powerful Tool Promises To Change The Way Scientists View Proteins
Aquaria, a publicly available web resource that streamlines and simplifies the process of gleaning insight from 3D protein structures, is fast, easy-to-use and contains twice as many models as all other similar resources combined.
Rapid Test Kit Detects Dengue Antibodies from Saliva
IBN’s MedTech innovation simplifies diagnosis of infectious diseases.
“Unprecedented Sensitivity and Specificity” in Ovarian Cancer
Study of the use of the Parsortix system as a clinical application in the detection and treatment of ovarian cancer patients.
Nanoparticle Lights Up Artery-Clogging Plaque
A new imaging agent that may light up dangerous plaque in arteries is to be evaluated in a clinical trial.
Study Uncovers Range of Molecular Alterations in Head and Neck Cancers
TCGA tumor genome sequencing analyses offer new insights into the effects of HPV and smoking, and find genomic similarities with other cancers.
Beating The Clock: New Treatment For Rabies Developed
University of Georgia researchers have developed a new treatment for rabies.
Scroll Up
Scroll Down
Return
The Versatility of Fragment Screening Approaches and the Application of Fragment Binding Information in Durg Discovery
Stefan Geschwindner, AstraZeneca, speaking at Discovery Chemistry Congress 2012.
Date Posted: Friday, November 23, 2012
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



AstraZeneca Forms CRISPR Collaborations
AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform.
Thursday, January 29, 2015
AstraZeneca To Expand Its Frederick Biologics Manufacturing Center
$200+ million investment to support company’s maturing biologics pipeline.
Tuesday, November 25, 2014
AstraZeneca Buys Rights to Almirall Respiratory Franchise
AstraZeneca agrees an initial consideration of $875 million on completion, which may rise to $1.22 billion in development, launch, and sales-related milestones.
Monday, August 04, 2014
AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca system implemented with input from Tessella wins 2014 Bio-IT World Best Practices Award
Award winning Clinical & Health IT system allows AstraZeneca to respond rapidly to safety concerns and swiftly identify risk factors for adverse events, protecting trial participants while rescuing trials from costly late-stage failure.
Saturday, May 10, 2014
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance Assets
Global agreement strengthens AstraZeneca’s commitment to diabetes.
Monday, December 23, 2013
AstraZeneca to Invest £120 Million in New Manufacturing Facility
AstraZeneca invests to continue production of Zoladex, an injectable treatment for patients with prostate cancer.
Tuesday, November 12, 2013
AstraZeneca to Acquire Pearl Therapeutics to Strengthen Respiratory Portfolio
Pearl Therapeutics is focused on the development of inhaled small-molecule therapeutics for respiratory disease.
Wednesday, June 12, 2013
AstraZeneca to Acquire Omthera Pharmaceuticals
Acquisition includes the take-over of NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio.
Wednesday, May 29, 2013
AstraZeneca and BMS Receive Award from Major Medical Association
Companies received the American College of Endocrinology (ACE) Philanthropic Award at the AACE 22nd Annual Scientific & Clinical Congress in Phoenix, Arizona on May 4, 2013.
Thursday, May 09, 2013
AstraZeneca’s Biologics Unit Acquires AlphaCore Pharma
AlphaCore Pharma is a biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase enzyme.
Wednesday, April 03, 2013
AstraZeneca Announces Changes to Senior Executive Team
Company’s President and Executive Vice President will leave the company at the end of January.
Monday, January 28, 2013
Ten Pharmaceutical Companies Unite
Ten leading biopharmaceutical companies announced that they have formed a non-profit organization to accelerate the development of new medicines.
Wednesday, September 26, 2012
AstraZeneca and the Broad Institute Collaborate
Partnership to advance discovery of antibacterial and antiviral agents.
Tuesday, September 11, 2012
 
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn